Zeitschrift für Pharmakokinetik und experimentelle Therapeutik

Offener Zugang

Unsere Gruppe organisiert über 3000 globale Konferenzreihen Jährliche Veranstaltungen in den USA, Europa und anderen Ländern. Asien mit Unterstützung von 1000 weiteren wissenschaftlichen Gesellschaften und veröffentlicht über 700 Open Access Zeitschriften, die über 50.000 bedeutende Persönlichkeiten und renommierte Wissenschaftler als Redaktionsmitglieder enthalten.

Open-Access-Zeitschriften gewinnen mehr Leser und Zitierungen
700 Zeitschriften und 15.000.000 Leser Jede Zeitschrift erhält mehr als 25.000 Leser

Abstrakt

Quantification of Rosuvastatin and its Metabolites through HPLC-Mass Spectrometry for Pharmacokinetic Analysis

Havid Vilava

The pharmacokinetic analysis, the accurate quantification of drug compounds and their metabolites is crucial to understanding their behavior within the body. This study presents a comprehensive investigation into the pharmacokinetics of rosuvastatin and its metabolites utilizing a robust analytical approach combining High- Performance Liquid Chromatography (HPLC) with Mass Spectrometry (MS). The developed HPLC-MS method demonstrates exceptional sensitivity and selectivity, allowing for the simultaneous quantification of rosuvastatin and its metabolites in complex biological matrices. The method validation showcases its precision, accuracy, linearity, and robustness, enabling reliable measurements of concentrations over various time points. A pharmacokinetic study was conducted following the administration of rosuvastatin in a cohort of subjects. Blood samples were collected at predetermined intervals, processed, and analyzed using the established HPLC-MS method. The resulting concentration-time profiles of rosuvastatin and its metabolites provided insights into absorption, distribution, metabolism, and excretion patterns. The findings elucidate the metabolic pathways of rosuvastatin, shedding light on the formation of metabolites and their subsequent kinetics. The obtained pharmacokinetic parameters contribute to a deeper understanding of the drug's behavior within the human body, potentially guiding dosing regimens and therapeutic strategies. In conclusion, the integration of HPLC with mass spectrometry has proven to be a valuable tool for investigating the pharmacokinetics of rosuvastatin and its metabolites. This analytical approach not only advances our comprehension of drug metabolism and disposition but also holds promise for optimizing treatment approaches in individuals requiring rosuvastatin therapy.